Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dianthus Therapeutics (DNTH) Shares Outstanding (2017 - 2025)

Dianthus Therapeutics has reported Shares Outstanding over the past 8 years, most recently at $42.9 million for Q3 2025.

  • Quarterly results put Shares Outstanding at $42.9 million for Q3 2025, up 45.93% from a year ago — trailing twelve months through Sep 2025 was $42.9 million (up 45.93% YoY), and the annual figure for FY2024 was $31.1 million, up 109.99%.
  • Shares Outstanding for Q3 2025 was $42.9 million at Dianthus Therapeutics, up from $32.2 million in the prior quarter.
  • Over the last five years, Shares Outstanding for DNTH hit a ceiling of $60.6 million in Q3 2022 and a floor of $875279.0 in Q4 2022.
  • Median Shares Outstanding over the past 4 years was $29.4 million (2024), compared with a mean of $27.4 million.
  • Peak annual rise in Shares Outstanding hit 1592.92% in 2023, while the deepest fall reached 55.55% in 2023.
  • Dianthus Therapeutics' Shares Outstanding stood at $33.3 million in 2022, then crashed by 55.55% to $14.8 million in 2023, then surged by 109.99% to $31.1 million in 2024, then surged by 37.73% to $42.9 million in 2025.
  • The last three reported values for Shares Outstanding were $42.9 million (Q3 2025), $32.2 million (Q2 2025), and $32.1 million (Q1 2025) per Business Quant data.